SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful launch of its BlueBird-6 satellite, a critical milestone signifying the company's transition toward commercial scalability for direct-to-device broadband. The community is buzzing with excitement, anticipating significant future growth and contract announcements, though some express caution regarding valuation and a potential "sell the news" reaction. This event firmly positions ASTS as a major player in the rapidly evolving space-based cellular network industry.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Starfighters Space Inc

Starfighters Space Inc. (FJET), a recently public aerospace company, is trending due to extreme volatility driven by its low float and very high short interest. The community is fiercely divided, with many anticipating a significant short squeeze while others label it a pump-and-dump. There is widespread discussion about alleged market manipulation influencing its price action amidst this speculative fervor.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is a major talking point with significant anticipation surrounding its upcoming showcases of commercial quantum computing solutions at industry events. The community is deeply divided, with many optimistic about the company's potential for broad adoption and future partnerships, while a vocal segment expresses caution regarding valuation and recent executive stock sales. This reflects broader market debate on the commercial readiness and investment risks within the evolving quantum computing sector.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is currently trending following its announced inclusion in the S&P MidCap 400 index, a move expected to generate significant institutional buying pressure and boost market visibility. The community is actively discussing this catalyst as a major inflection point for the pure-play automation leader, anticipating strong long-term growth driven by its Agentic AI solutions and robust financial position. Many investors see this as a key moment, despite some discussions around short-term profit-taking.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending as Sanofi moves to acquire the company for $15.50 per share in a $2.2 billion deal, significantly expanding Sanofi's vaccine pipeline with DVAX's hepatitis B vaccine and developing shingles treatment. The community is celebrating the premium offered, while also speculating on the strategic value Sanofi may see in DVAX's recent licensing of an oral COVID-19 vaccine program. This acquisition has sparked broader conversations about potential interest in smaller biotech companies within the sector.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending due to significant insider share accumulation by its CEO, fueling speculation and high retail interest in this low-float Hong Kong-based company. The community is actively debating its extreme volatility and whether it can replicate past parabolic runs seen in similar small-cap plays, despite ongoing discussions about its valuation and business model.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is trending on widespread anticipation for the FDA's decision on Narsoplimab, a first-in-class drug for TA-TMA, with many speculating on an early approval before the December 26th PDUFA date. The community is actively discussing potential for a significant price surge fueled by high unmet medical need, strong trial data, and the recent $2.1 billion Novo Nordisk deal that has bolstered Omeros's financial position. This binary event has triggered intense debate over short manipulation and a possible "shakeout" of shares ahead of what many believe will be a transformative approval.

Volkswagen AG engages in the business of developing vehicles and components for the brands of the group. It operates through the following segments: Passenger Cars and Light Commercial Vehicles; Commercial Vehicles; Power Engineering; and Financial Services. The Passenger Cars and Light Commercial Vehicles segment includes developing vehicles, engines, and vehicle software; producing and selling passenger cars and light commercial vehicles; and the corresponding genuine parts business. The Commercial Vehicles segment focuses on trucks, buses, corresponding genuine parts business, and related services. The Power Engineering segment is involved in large-bore diesel engines, turbomachinery, and propulsion components business. The Financial Services segment provides dealer and customer financing, leasing, banking, insurance, and fleet management services. The company was founded on May 28, 1937 and is headquartered in Wolfsburg, Germany.

Volkswagen AG - ADR

Volkswagen AG is trending due to its significant new joint venture and investment in Rivian for advanced electrical architecture and software, aiming to accelerate its EV strategy and enhance competitiveness. This move comes as the company navigates extensive cost-cutting measures, labor disputes over potential plant closures and wage adjustments, and a challenging global EV market, especially in China and Europe. The community is actively discussing whether these strategic partnerships and internal restructuring will successfully position VW to overcome industry headwinds and intense competition.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is generating significant buzz following the early FDA approval of its lead drug, KOMZIFTI, for relapsed or refractory NPM1-mutated AML, which also triggered a substantial milestone payment from Kyowa Kirin. The community is actively debating KOMZIFTI's perceived superior safety profile and once-daily dosing compared to competitors, fueling strong bullish sentiment around its potential for frontline AML treatment and further data presentations at the upcoming ASH conference. Despite initial 'sell the news' reactions, many investors consider the stock undervalued given its strong financial position and vast market opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nvidia $NVDA has reportedly told Chinese clients that it plans to resume shipping its H200 GPU before February, with reports suggesting initial shipments could total 5,000 to 10,000 servers, or about 40,000 to 80,000 GPUs. 
 
$AMD $BABA $BIDU

beguin beguin

StockTwits Web

Advanced Micro Devices Inc

Alibaba Group Holding Ltd

Baidu Inc - ADR

 has reportedly told Chinese clients that it plans to resume shipping its H200 GPU before February, with reports suggesting initial shipments could total 5,000 to 10,000 servers, or about 40,000 to 80,000 GPUs. 
 
